News

FDA tells food producers to cut the trans fat


 

References

Food manufacturers will no longer be allowed to include partially hydrogenated oils (PHOs) in human food when a new requirement by the Food and Drug Administration becomes effective.

The FDA finalized its determination that PHOs, which are the primary dietary source of artificial trans fat in processed foods, are not “generally recognized as safe” for use in human food. This action was preceded by the FDA having requested comment on a tentative version of the determination in a Nov. 8, 2013 notice.

©Mark Poprocki/Thinkstockphotos.com

“This determination is based on extensive research into the effects of PHOs, as well as input from all stakeholders received during the public comment period,” said Susan Mayne, Ph.D., director of the FDA’s Center for Food Safety and Applied Nutrition, in a written statement.

The order follows the FDA’s requirement that food manufacturers include trans fat content information on nutrition facts labels, which became effective in 2006. Currently, the FDA allows companies to state on the labels of foods containing less than 0.5 grams of trans fat per serving that such foods are made with 0 grams of trans fat.

The FDA’s new requirement “is expected to reduce coronary heart disease and prevent thousands of fatal heart attacks every year,” said the FDA’s Acting Commissioner Stephen Ostroff in the written statement.

The agency is giving food producers 3 years to remove PHOs from their products and/or petition the FDA to permit specific uses of PHOs. A notice of the order is scheduled to be published in the Federal Register tomorrow (June 17, 2015).

klennon@frontlinemedcom.com

Recommended Reading

Maternal age, cardioseptal defects are major risk factors for peripartum thrombosis
MDedge ObGyn
Hormone therapy 10 years post menopause increases risks
MDedge ObGyn
Hot flashes in younger women may signal cardiac risk
MDedge ObGyn
Apple’s ResearchKit
MDedge ObGyn
Gout increases risk of vascular disease, especially for women
MDedge ObGyn
Class of 2015: New drugs projected to earn billions and billions
MDedge ObGyn
Newer oral contraceptives pose higher VTE risk
MDedge ObGyn
Experts: Office workers should stand more
MDedge ObGyn
Newborn’s pulmonary hypertension risk up slightly after SSRI exposure in pregnancy
MDedge ObGyn
Uncomplicated pregnancies in women with lupus may not boost risk for CV events
MDedge ObGyn